Abbott Laboratories
(NYSE: ABT)
36.21
-1.30
-3.47%
-1.30
-3.47%
MORE ON ABT
COMPANY INFORMATION
| Exchange: | New York Stock Exchange |
| Stock: | Abbott Laboratories |
| Industry: | Medical Devices |
| Employees: | 91,000 |
DESCRIPTION
| Abbott Laboratories is an Illinois corporation, incorporated in 1900. The Company discovers, develops, manufactures and sells a broad and diversified line of health care products. It has five reportable revenue segments, Proprietary Pharmaceutical Products, Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Proprietary Pharmaceutical Products include Humira®, for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, psoriasis, juvenile idiopathic arthritis, and Crohn's disease; TriCor®, Trilipix®, Simcor®, and Niaspan®, for the treatment of dyslipidemia; Kaletra®, also marketed as Aluvia®, and Norvir®, protease inhibitors for the treatment of HIV infection. Established Pharmaceutical Products include Creon®, for the treatment of pancreatic exocrine insufficiency associated with several underlying conditions, including cystic fibrosis and chronic pancreatitis; Influvac®, an influenza vaccine available during flu season; Serc®, for the treatment of Ménière's disease and vestibular vertigo; Brufen®, for the treatment of pain, fever and inflammation. Diagnostic Products include immunoassay and clinical chemistry systems, including ARCHITECT® and ABBOTT PRISM®; the m2000™, an instrument that automates the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents including HIV, HBV, HCV, HPV, and CT/NG; the Vysis® product line of genomic-based tests, including the PathVysion® HER-2 DNA probe kit; the UroVysion® bladder cancer recurrence kit; and the Vysis ALK Break Apart FISH Probe Kit, the only FDA-approved companion diagnostic to Pfizer's approved non-small-cell lung cancer therapy XALKORI®. Nutritional Products include various forms of prepared infant formula and follow-on formula, including Similac®Advance®, Similac® Advance® with EarlyShield®, Similac®, Similac® with Iron, Similac Sensitive®, Similac Sensitive® RS, Similac Go&Grow®, Similac® NeoSure®, Similac® Organic, Similac Special Care®, Similac® Total Comfort®, Isomil® Advance®, Isomil®, Alimentum®, Gain®, and Grow®; adult and other pediatric nutritional products, including Ensure®, Ensure Plus®, Ensure® Muscle Health, Ensure® (with Nutrivigor®), Glucerna®, Glucerna® Hunger Smart®, PediaSure®, PediaSure Sidekicks®, EleCare®, Juven®, Abound®, and Pedialyte®; nutritional products used in enteral feeding in health care institutions, including Jevity®, Glucerna® 1.2 Cal, Glucerna® 1.5 Cal, Osmolite®, Oxepa®, Freego (Enteral Pump) and Freego® sets, and Nepro®; and Zone Perfect® bars and the EAS® family of nutritional brands, including Myoplex® and AdvantEdge®. Vascular Products include, Xience Xpedition®, Xience Prime®, Xience nano™, and Xience V®, drug-eluting stent systems developed on the Multi-Link Vision® platform; Multi-Link 8®, Multi-Link Vision® and Multi-Link Mini Vision®, coronary metallic stents; TREK® and Voyager®, balloon dilatation products; Absorb®, a drug-eluting bioresorbable vascular scaffold. The main products in the Company’s other businesses include blood glucose monitoring meters, test strips, data management software and accessories for people with diabetes, including the FreeStyle® product line, and medical devices for the eye, including cataract surgery, LASIK surgery, contact lens care products, and dry eye products. The development, manufacture, marketing, sale, promotion, and distribution of its products are subject to comprehensive government regulation by various federal, state, and local agencies, both domestic and international. |
DATA PROVIDERS
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
RECENT QUOTES
WATCHLIST
You're not signed in
You’re not signed in to MSN Money, so you’re seeing the Watchlist that is tied to your computer. For a more consistent Watchlist experience, sign in to MSN Money.
Learn more
Sponsored by:
MARKET UPDATE
[BRIEFING.COM] Equities ended on their lows with the S&P 500 down 1.4%. The S&P entered today's session with a week-to-date gain of 1.5% as investors expected reassuring words from today's Federal Open Market Committee Statement. Stocks traded with s
...
More
MORE MARKET NEWS
Sponsored by: